Imbria Pharmaceuticals is dedicated to translating scientific understanding of cellular metabolism into innovative medicines aimed at improving the lives of patients with limited or inadequate treatment options. Founded by doctors, the company focuses on developing treatments that enhance or restore cellular energy production, particularly targeting cardiometabolic diseases. Imbria's mission is driven by a deep scientific interest in cellular metabolism and mitochondria, guided by strong values and a code of business conduct.
Imbria Pharmaceuticals has made significant strides in its field, notably presenting results from the IMPROVE-HCM trial of Ninerafaxstat at the American College of Cardiology's late-breaking clinical trial session. These results were also published in the Journal of the American College of Cardiology (JACC), underscoring the company's impact on advancing medical science. Through its innovative approach, Imbria continues to make meaningful contributions to patient care and treatment options.
